Ravasio, R., Viti, R. and Roscini, A. S. (2023) “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”, AboutOpen, 10(1), pp. 13–21. doi: 10.33393/ao.2023.2515.